A fully integrated specialty pharmaceutical company with industry-leading transdermal expertise
Developing and commercializing therapies for women’s menopausal health concerns has been a cornerstone of Noven’s business since it was founded in 1987.
In this area, Noven developed the first FDA-approved adhesive matrix estrogen therapy patch, the first approved combination (two-drug) patch, COMBIPATCH® (estradiol/norethindrone acetate transdermal system) and the planet’s smallest estrogen patch, MINIVELLE® (estradiol transdermal system). Noven also manufactures hormone therapy patches that are marketed and sold by partners around the world. Noven's authorized generic division, Grove Pharmaceuticals, offers our products to the generic marketplace as Authorized Generics, providing patients with brand quality at a more affordable price.